Table 4.

Baseline immunosuppression characteristics and modification during the infection

Baseline immunosuppression therapy	Overall, n (%)	No modification, n (%)	Reduction, n (%)	Discontinuation, n (%)
Single agent
CNIs	16 (28)	12 (75)	2 (12.5)	2 (12.5)
Cyclosporine	3 (5)	2 (67)	0	1 (33)
Tacrolimus	13 (29)	10 (77)	2 (15)	1 (8)
mTORi	2 (4)	1 (50)	0	1 (50)
Everolimus	1 (2)	1 (100)	0	0
Sirolimus	1 (2)	0	0	1 (100)
MMF	2 (3)	0	0	1 (100)
Steroid	1 (2)	1 (100)	0	0
Two or more agents
CNIs+MMF	21 (37)	7 (33)	6 (29)	8 (38)
CNIs	–	–	5	1
MMF	–	–	1	7
CNIs+mTORi	3 (5)	1 (33.3)	1 (33.3)	1 (33.3)
CNIs	–	–	1	0
mTORi	–	–	0	1
CNIs+steroids	9 (16)	1 (11.2)	4 (44.4)	4 (44.4)
CNIs	–	–	4	4
Steroids	–	–	0	0
CNIs+AZA	1 (2)	1 (100)	0	0
mTORi +MMF	2 (3)	1 (50)	0	1 (50)
mTOR	–	–	0	1
MMF	–	–	0	0

AZA, azathioprine; CNIs, calcineurin inihibitors, including cyclosporine and tacrolimus; MMF, mycophenolate mofetil; mTORi, mammalian target of rapamycin inhibitor, including sirolimus and everolimus.